Abbott ESA Chagas Assay Post-Market Study
ESA
1 other identifier
interventional
63
1 country
2
Brief Summary
The study is conducted to meet an FDA post market commitment to collect and report data on the performance of the ESA Chagas assay. A minimum of 50 donor specimens that are FDA-licensed ABBOTT PRISM Chagas repeatedly reactive (RR)will be tested with the ABBOTT ESA Chagas assay. In addition, minimum of 300 ABBOTT PRISM Chagas nonreactive (NR) unidentified donor specimens will be tested with ABBOTT ESA Chagas assay.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2012
Shorter than P25 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2012
CompletedFirst Submitted
Initial submission to the registry
August 8, 2012
CompletedFirst Posted
Study publicly available on registry
August 10, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2012
CompletedResults Posted
Study results publicly available
February 20, 2014
CompletedFebruary 20, 2014
January 1, 2014
5 months
August 8, 2012
January 8, 2014
January 8, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
ESA Chagas Testing of US Blood Donor Specimens Repeatedly Reactive by ABBOTT PRISM Chagas
Up to six months
Secondary Outcomes (1)
ESA Testing of Preselected Donor Specimens Nonreactive by ABBOTT PRISM Chagas
Up to six months
Study Arms (1)
Testing Donor Specimens with ESA Chagas
OTHERTest blood donor specimens that are ABBOTT PRISM Chagas Repeatedly Reactive with ESA Chagas. Donors will be asked to return for a follow-up blood draw.
Interventions
Donors will be asked to return for a follow-up blood draw.
Eligibility Criteria
You may qualify if:
- Blood donor specimen documented as PRISM Chagas repeatedly reactive
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
LifeSource
Rosemont, Illinois, 60018, United States
American Red Cross
Gaithersburg, Maryland, 20877, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Barbara Kaesdorf, Associate Director Clinical Affairs
- Organization
- Abbott
Study Officials
- PRINCIPAL INVESTIGATOR
Susan Stramer, Ph.D.
American National Red Cross
- PRINCIPAL INVESTIGATOR
Sharon Gordon, MS, MBA, MT
LifeSource
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- GT60
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 8, 2012
First Posted
August 10, 2012
Study Start
July 1, 2012
Primary Completion
December 1, 2012
Study Completion
December 1, 2012
Last Updated
February 20, 2014
Results First Posted
February 20, 2014
Record last verified: 2014-01